Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30379934 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53USP2 | |
| SCHEMBL10019467 | 0.84 | CYP3A4 (0.78) | CYP3A4SMN1; SMN2MAPTTP53USP2 | |
| Deacetoxy-7-Oxogedunin SCHEMBL20639417 | 0.80 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53USP2 | |
| Deacetoxy-7-Oxogedunin SCHEMBL12998441 | 0.80 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53USP2 | |
| Deacetylgedunin SCHEMBL10019480 | 0.79 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53USP2 | |
| Gedunin SCHEMBL23134885 | 0.75 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53USP2 | |
| Gedunin SCHEMBL598969 | 0.75 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53USP2 | |
| SCHEMBL12239950 | 0.75 | CYP3A4 (0.77) | CYP3A4SMN1; SMN2MAPTTP53USP2 | |
| Gedunin SCHEMBL14197009 | 0.75 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53USP2 | |
| Gedunin SCHEMBL12998444 | 0.75 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023018273-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF PIGMENT DISEASE | 연세대학교 산학협력단 | 2023-02-16 | — | — | WO | claimed |
| US-11873486-B2 | Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023018273-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF PIGMENT DISEASE | 연세대학교 산학협력단 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018273-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF PIGMENT DISEASE | 연세대학교 산학협력단 | 2023-02-16 | — | — | WO | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | CYP3A4 4800/4885SMN1; SMN2 210/4885MAPT 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.